Valproate Treatment in an ALS Patient Carrying a c.194G>A Spastin Mutation and SMN2 Homozygous Deletion
Here we report the case of an ALS patient found to carry both a novel heterozygous change (c.194G>A) within the spastin gene and a homozygous deletion of the SMN2 gene. The patient was started on valproic acid (VPA, 600 mg/die per os) considering the capacity of this drug of increasing survival m...
Saved in:
Main Authors: | Lucio Tremolizzo, Gessica Sala, Elisa Conti, Virginia Rodriguez-Menendez, Antonella Fogli, Angela Michelucci, Paolo Simi, Silvana Penco, Christian Lunetta, Massimo Corbo, Carlo Ferrarese |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Case Reports in Neurological Medicine |
Online Access: | http://dx.doi.org/10.1155/2014/216094 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Homozygous 6-bp deletion of IGFALS in a prepubertal boy with short stature
by: Hibiki Doi, et al.
Published: (2024-07-01) -
Targeting MDM2 affects spastin protein levels and functions: implications for HSP treatment
by: Francesca Sardina, et al.
Published: (2025-02-01) -
Valproate Induced Hypertensive Urgency
by: Mauran Sivananthan, et al.
Published: (2016-01-01) -
Case report: Novel multi-exon homozygous deletion of ZBTB24 causes immunodeficiency, centromeric instability, and facial anomalies syndrome 2
by: Yan Long, et al.
Published: (2025-01-01) -
Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer
by: Natalia Gorbokon, et al.
Published: (2025-01-01)